Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium supplementation and RAAS inhibition in chronic kidney disease and healthy subjects
NL-OMON48661Recruiting
- Sponsor
- Inwendige geneeskunde/Nefrologie
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of lisinopril, potassium chloride and potassium citrate in chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by Inwendige geneeskunde/Nefrologie. Primary endpoint: Serum potassium. Started Apr 2019; status: recruiting.
02
Drugs
lisinoprilpotassium chloridepotassium citrate
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON48661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48661.